Objectives: To quantify Gleason score (GS) heterogeneity within multiparametric magnetic resonance imaging (MRI)-targeted prostate biopsies and to determine impact on National Comprehensive Cancer Network (NCCN) risk stratification.
T he current standard of reference for prostate tissue sampling is transrectal ultrasound (TRUS)-guided 12-core systematic biopsy (SB). This approach, however, often fails to detect significant disease because of inadequate target definition by TRUS, as evidenced by the 20% to 30% Gleason score (GS) upgrading seen at the time of radical prostatectomy. [1] [2] [3] [4] [5] [6] The advent of multiparametric magnetic resonance imaging (mpMRI) has resulted in better visualization of intraprostatic lesions that were not previously detectable with computed tomography imaging or with TRUS. [7] [8] [9] The fusion of mpMRI with real-time TRUS during biopsies in the clinic has permitted the use of MRI data to target areas at greatest risk for having prostate cancer. 10 As the evidence for using targeted biopsy (TB) mounts, the downstream implications for the treating radiation oncologist are far from understood. The goal is to be able to reliably determine the nature and the extent of disease before making a treatment decision. The identification of the highest GS is a critical piece of information in our current risk stratification model. With TBs we have the ability to more accurately sample areas at high risk of harboring prostate cancer, but there are many unanswered questions regarding the ideal approach to finding the highest GS within a particular target. If the MRI target is homogenous, perhaps 1 TB is sufficient to accurately classify the highest GS. However, if there is significant intraprostatic target heterogeneity, it may be necessary to take multiple targeted biopsies from a particular lesion to quantify the true disease pathology. The clinical implication of how to integrate TB GS information into risk stratification schemes, which are currently based on SB, also deserves further study.
To this end, we reviewed the pathology reports of patients who had undergone TBs and were referred to our radiation oncology clinic. We then analyzed TB GS heterogeneity and determined the impact of changes in GS on National Comprehensive Cancer Network (NCCN) risk group stratification.
MATERIALS AND METHODS

Patient Selection
This was an Institutional Review Board-approved retrospective pilot study on a consecutive series of patients with biopsy-proven prostate cancer who were referred to the University of California, Los Angeles Radiation Oncology Department. All patients had a 3T mpMRI followed by SB and TBs with the Artemis (Eigen; Grass Valley, CA) MRI-US fusion device between 2012 and 2015. Digital rectal exam was performed for clinical staging and patients had at least 1 pretreatment prostate specific antigen (PSA) blood test. Patients who had not undergone TB and those with recurrent disease were excluded.
MRI Technique
The MRI technique has been described in our previous publication. 11 mpMRI was performed with a 3T Siemens SOMATOM Trio Tim or 3T Skyra scanner (Siemens, Erlangen, Germany) using a multichannel external phased-array body coil. mpMRI sequence parameters included multiplanar (axial and coronal) T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging. Morphologic T2-weighted images were used for image interpretation. All images were interpreted by 1 of 3 experienced radiologists with expertise in prostate MRI. Each region of interest (ROI) within the prostate was identified and then assigned an institution-standardized image grade on a scale of 1 to 5 (1 = clinically significant disease highly unlikely to 5 = clinically significant disease is highly likely).
Biopsy Technique
All men had TBs and SBs performed by a single, experienced University of California, Los Angeles urologist using the Artemis device with a spring-loaded biopsy gun and 18-G needles, as described previously. 12 The ROIs identified on MRI were electronically loaded into Artemis before beginning a conventional TRUS biopsy session in the urology clinic. Fusion of the MRI and real-time US was performed by the device software. For TB, 1 core was obtained every 3 mm along the longest axis of the lesion before SB sampling. SB sampling with Z10 cores was then performed as preselected by the Artemis device, independent of the MRI results. A minimum of 10 cores was selected to limit the number of possible TB upgrades because of inadequate systematic sampling.
Heterogeneity and Risk Stratification Analyses
Patients were included in the heterogeneity portion of the study only if Z2 positive cores were found on TB so that a comparison within the target could be made. Analysis was performed based solely upon the results of TB by comparing the core with the lowest GS to the core with the highest GS. SB results were not included. Heterogeneity was defined as a difference of at least 1 GS between cores. Therefore, GS 3 + 4 versus 4 + 3 was not considered heterogenous for this analysis. Further analysis was performed to determine if heterogeneity was associated with any of the following factors: PSA, max tumor diameter on MRI, apparent diffusion coefficient (ADC), MRI suspicion score, prostate volume, SB GS, and T-stage. Student t tests assuming unequal variance were used to compare the means of evaluated factors for correlation. A P-value of <0.05 was used to indicate statistical significance.
The effect of TB on NCCN risk group classification (upstaging) was determined by examining T-stage, PSA, and GS. The impact of heterogeneity on risk grouping was performed by staging patients based on the lowest GS within the target lesion, and then by the highest GS within the target lesion. Upstaging was defined as an upward change in risk group (low risk to intermediate risk, intermediate risk to high risk, or low risk to high risk). For targets with only 1 positive core, the same GS was used for both high and low, and the patient was not upstaged. For targets with no positive cores, the systematic GS was used and the patient was not upstaged. Similar metrics were used to determine the rate of upstaging between systematic and combined (targeted + systematic) biopsy.
RESULTS
There were a total of 53 patients included in the study. The median age was 72 years (56 to 83) and the PSA mean ± SD was 9.3 ± 5.8 ng/dL. Further patient characteristics are summarized by risk group in Table 1 . The mean number of SB cores obtained was 12 (10 to 16), and the mean number of positive SB cores per patient was 2.9 (24.1%).
A total of 73 target lesions were identified on mpMRI and biopsied using Artemis ultrasound fusion. The results are summarized in Table 2 . The mean number of target lesions biopsied per patient was 1.38 (range, 1 to 3). A mean of 4.3 cores (range, 3 to 7) were taken from each target; 2.7 (63%) cores were positive for cancer. All 53 patients had at least 1 positive TB. Of the 73 targets, 10 (14%) were negative, 12 (16%) had a single positive core, and 51 (70%) had 2 or more cores positive for prostate cancer.
Heterogeneity analysis was performed only on the 51 targets with 2 or more positive cores. There was no difference in the GS between cores in 23/51 (45%) of the qualifying target lesions. In the remaining 28/51 (55%), there was a difference of at least 1 GS between the cores. Of these 28 heterogenous targets, 20/28 (71%) had a GS difference of 1 and 8/ 28 (29%) had a GS difference of 2 to 3 (2 patients GS 6 to 8, 4 GS 6 to 9, and 2 GS 7 to 9). Table 3 summarizes the comparison of PSA, ADC, maximum tumor diameter, MRI prostate volume, and MRI suspicion score in targets with and without heterogeneity. None of the evaluated factors demonstrated a significant correlation, but there was a trend for patients with heterogeneity to have a lower ADC (882 vs. 956 mm 2 /s, P = 0.081) and a higher MRI suspicion score.
The effect of heterogeneity on NCCN risk group was analyzed using TB low GS versus high GS to stratify patients (Table 4) . We also looked at the overall impact of TB by comparing risk groups using the GS from SB alone with the overall highest using a combination of the 2 (SB + TB). Using only SB resulted in 30% low-risk, 49% intermediate-risk, and 21% high-risk patients. Combining the high GS from TB with the SB results resulted in 4% low-risk, 54% intermediate-risk, and 42% high-risk patients. The low GS on TB combined with SB resulted in 17%, 55%, and 28% in each risk group, respectively. Overall, 43% (n = 23) of the patients had a higher GS detected on TB versus SB. This led to 38% (n = 20) of patients being placed into a higher risk group when adding information gleaned from the TB to the SB results, including 5 patients categorized as low-risk on SB moving to high-risk disease based on the TB. Figure 1 provides a graphical illustration of the risk group differences.
DISCUSSION
Growing data demonstrates MRI-ultrasound fusion TB improves prostate cancer detection compared with office-based 12-core systematic TRUS-guided biopsy. A recent prospective study on 1042 men undergoing this technique demonstrated improved detection rates for clinically significant prostate cancers (GSZ7). 13 The role of TBs will likely increase as further evidence mounts. The primary goal of this technique has been to enhance cancer detection, but less consideration has been given to its impact on definitive treatment decisions. In this study we also evaluated the impact of TB GS heterogeneity on NCCN risk stratification.
Our results demonstrated heterogeneity within mpMRItargeted lesions, with 55% of foci showing a difference in GS, including a modest number of GS 6 to 8-9 differences. We also calculated that the heterogeneity has the potential to impact NCCN risk grouping. This demonstrates that approaching TB with a single core may be inadequate. Rather, taking 1 core every 3 mm across the ROI, as performed at our institution, may provide a more accurate assessment of the true significance of a designated target. 14 However, it is beyond the scope of our analysis to be able to determine the ideal number of targeted biopsies that need to be performed to optimize the chances of finding the highest GS within a target.
The addition of TB to SB reduced the low-risk group substantially (30% to 4%) and doubled the number of high-risk patients (21% to 42%). There was no apparent change in intermediate-risk because a similar number of cases moved from low risk to intermediate risk as those moving from intermediate risk into high risk. Our rate of upstaging (38%) when adding TB results to SB is fairly consistent with the literature and confirms the usefulness of using a combined approach. 11, 15, 16 How then should this information be used? Should a patient determined to have high-risk prostate cancer using TB be treated the same way as when they are placed in this risk group based on SB? It may be that such cases would be overtreated with multiple modalities when they might equally well be treated with a single modality, such as brachytherapy alone. 17 This concept of risk inflation from TBs is not novel and has been discussed previously. 18 However, there is currently little data in the literature to help answer this question.
We also attempted to determine potential associated factors for GS heterogeneity but none of the outcome predictors we evaluated were statistically associated in our study. There was a trend with ADC and MRI suspicion score and as this was a pilot study with a low number of patients, a larger sample may have been significant. This conceptually appears reasonable, as the MRI measures are surrogates of disease aggressiveness, suggesting that more aggressive disease may be associated with higher GS heterogeneity. This is consistent with radical prostatectomy studies showing a greater continuum of GS with aggressive disease compared with a more homogenous distribution in lower risk disease. 19 Although we did not have a direct comparison with prostatectomy available in our population, there are several series that have examined this concept of grade heterogeneity on whole mount specimens. One such study found that 84% of multifocal cancers showed heterogeneity across foci. 20 However, they also showed that 58% of single foci contained just a single grade while 42% had 2 or more grades of cancer. Similar findings have been demonstrated in a more recent analysis that found that 50% of tumors harbored at least 3 different histologic grades. 19 These findings are very similar to our 55% rate of heterogeneity within a target. Complicating these findings is the concept of multifocality, whereas high as 60% to 90% of prostate cancers may harbor multiple foci. 21 With this in mind, it is possible that as tumor volume increases over time, the foci culminate together effectively fusing into a single lesion. Because of this, a "single" target on MRI may represent the confluence of several foci, thus contributing the finding of heterogeneity in this study. Prostatectomy specimens have indirectly supported this finding although the theory is still being debated. 20 It is more likely that heterogeneity may be a result of the evolution of low-grade to high-grade disease within a single foci. This theory is supported by data from Aihara et al 19 where prostatectomy specimens showed a high grade cancer within a larger, well-differentiated tumor 53% of the time, while 30% of cases showed a low grade cancer within a large, poorly differentiated tumor. This underscores the unpredictability of the source and progression of heterogeneity, but highlights its significance across multiple modalities. Limitations include that this was a pilot study representing a small subset of the total number of patients undergoing TB at our institution, and that it was a single-institution and retrospective experience. Given the small sample size, we were unable to stratify patients further to determine subgroups that may have had variable clinical impact. In addition, our cohort does not include men with negative biopsies who would not have been referred to our department. Another limitation is possible selection bias as we only studied cases with an mpMRI identifiable target. As it has been shown that mpMRI preferentially identifies more aggressive lesions and is less likely to detect low-risk foci, there may be an inclusion bias toward patients with aggressive disease, thus inflating the rate of upstaging. Finally, there was no clinicopathologic correlation from prostatectomy specimens for this subset. It is possible that we continue to underestimate the extent of disease with TB. 16 
CONCLUSIONS
Our study of MRI-ultrasound fusion-guided biopsies demonstrated that more than half of the TB are heterogenous with respect to GS. In addition, 43% of patients have a highergrade cancer detected on TB compared with standard TRUS SB. Inclusion of the TB information into NCCN risk group stratification shifted 38% of cases into higher risk group categories. These findings have potentially significant implications for patient management. How to best integrate this information into clinical practice will need further study. 
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Intermediate High FIGURE 1. Demonstrates the differences in NCCN risk groups for the 53 patients when stratified by biopsy method. Note that the proportion of low-risk patients sharply decreases (from 30% to 4%), while the high-risk group doubles (from 21% to 42%), when adding targeted biopsy (TB) to systematic biopsy (SB). "TB Low GS" refers to using the lowest Gleason score (GS) found on TB whereas "TB High GS" refers to using the highest GS found. The contrast of risk grouping between "TB Low GS" and "TB High GS" demonstrates that when using "TB Low GS" NCCN risk group distribution is similar to using SB alone whereas greater differences are seen with using "TB High GS." 
